Opinion on Biotech

Published within

« | 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | » »|

Type Product title / description Pub Price
Expert View
Expert View

AAN 2012: Novartis presents new data in an attempt to boost confidence in long-term use of Gilenya

In keeping with American Academy of Neurology meetings of recent years, multiple sclerosis once again dominated proceedings at AAN 2012. Novartis used the platform to present new data from the extension FREEDOMS II trial to support the long-term use of Gilenya, and provided Phase II results for siponimod in relapse remitting multiple sclerosis.

Published By Datamonitor
03 May 2012
CommentWire
CommentWire

Genzyme/Sanofi: Aubagio's TOWER results fail to rise above the competition

New positive data from a pivotal Phase III trial of Genzyme's Aubagio will serve to support its anticipated approval in the US and EU, demonstrating significant reduction in annualized relapse rate. Despite these positive results, the drug will still face fierce competition from marketed oral Gilenya and Biogen's pipeline oral candidate BG-12, given their far superior efficacy profiles.

Published By Datamonitor
06 Jun 2012
CommentWire
CommentWire

Genentech/Roche: trial success prompts Perjeta approval

Genentech, a member of the Roche Group, has announced FDA approval of Perjeta in combination with Herceptin and docetaxel for the treatment of HER2-positive metastatic breast cancer. Perjeta's approval will enhance Roche's extensive portfolio of HER2-targeted therapies and help maintain sales revenue after Herceptin's patent expires.

Published By Datamonitor
13 Jun 2012

« | 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | » »|

No help is available.